Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IFRX 
InflaRx N.V. (IFRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IFRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.85
1 Year Target Price $3.85
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.33% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 108.40M USD | Price to earnings Ratio - | 1Y Target Price 3.85 |
Price to earnings Ratio - | 1Y Target Price 3.85 | ||
Volume (30-day avg) 7 | Beta 1.3 | 52 Weeks Range 0.71 - 2.81 | Updated Date 08/29/2025 |
52 Weeks Range 0.71 - 2.81 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.1729 | Actual -0.21 |
Profitability
Profit Margin - | Operating Margin (TTM) -32760.16% |
Management Effectiveness
Return on Assets (TTM) -38.33% | Return on Equity (TTM) -65.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24060627 | Price to Sales(TTM) 665.71 |
Enterprise Value 24060627 | Price to Sales(TTM) 665.71 | ||
Enterprise Value to Revenue 126.87 | Enterprise Value to EBITDA 0.5 | Shares Outstanding 67747104 | Shares Floating 56940785 |
Shares Outstanding 67747104 | Shares Floating 56940785 | ||
Percent Insiders 6.38 | Percent Institutions 24.97 |
Upturn AI SWOT
InflaRx N.V.
Company Overview
History and Background
InflaRx N.V. is a biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of life-threatening inflammatory diseases. Founded in 2007, InflaRx has focused on developing inhibitors targeting the complement system, specifically the C5a receptor.
Core Business Areas
- Drug Development: Researching, developing, and commercializing therapeutics that target the complement system to treat inflammatory diseases.
Leadership and Structure
InflaRx N.V. has a board of directors and a management team consisting of a CEO, CFO, and CSO. The company has a functional organizational structure, with departments dedicated to research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Vilobelimab (Gohibic): A first-in-class monoclonal anti-human complement factor C5a antibody. Approved in the US for the treatment of COVID-19 in critically ill adults. InflaRx holds global commercialization rights, revenue data is still developing. Competitors include companies focusing on anti-inflammatory therapies and other COVID-19 treatments.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and characterized by rapid technological advancements, regulatory hurdles, and extensive research and development. Significant opportunity exists for novel therapeutics targeting inflammatory diseases.
Positioning
InflaRx N.V. is positioned as a company focused on complement inhibition. Its competitive advantage lies in its expertise in C5a inhibition and its lead product, Vilobelimab.
Total Addressable Market (TAM)
The TAM for inflammatory diseases is substantial, estimated in the billions of dollars globally. InflaRx aims to capture a portion of this market with its novel therapies by addressing unmet medical needs in severe inflammatory conditions.
Upturn SWOT Analysis
Strengths
- Novel C5a inhibitor technology
- US FDA Approval for Vilobelimab
- Experienced management team
- Strong patent portfolio
Weaknesses
- Limited commercial infrastructure
- Reliance on a single product
- History of operating losses
- Small Market Cap
Opportunities
- Expansion into new indications for Vilobelimab
- Partnerships with larger pharmaceutical companies
- Expansion into new geographic markets
- Further development of pipeline candidates
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Pricing and reimbursement pressures
- Patent expirations
Competitors and Market Share
Key Competitors
- REGN
- LLY
- GILD
Competitive Landscape
InflaRx faces competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its targeted approach to complement inhibition and its focus on unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on clinical trial progress and regulatory approvals. The company has achieved significant milestones with its lead candidate.
Future Projections: Future growth depends on successful commercialization of Vilobelimab and expansion into new indications. Analyst projections vary based on market uptake and clinical trial outcomes.
Recent Initiatives: Recent initiatives include securing regulatory approval for Vilobelimab, expanding manufacturing capacity, and conducting clinical trials in new indications.
Summary
InflaRx N.V. is a high-risk, high-reward biopharmaceutical company with a novel technology platform and a recently approved product. While the company's limited resources and commercial infrastructure present challenges, the potential for Vilobelimab to address unmet medical needs in severe inflammatory conditions offers significant opportunity. Investors should closely monitor the company's commercial execution, clinical trial progress, and financial performance. The small market cap of the company should be considered.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- FDA
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. All data is based on publicly available information and may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InflaRx N.V.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-11-08 | Co-Founder, CEO & Executive Director Dr. Niels C. Riedemann M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.inflarx.de |
Full time employees 74 | Website https://www.inflarx.de | ||
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.